Published in Toxicol Appl Pharmacol on March 21, 2006
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel) (2011) 3.62
Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol (2007) 1.88
Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem Cell Biol (2008) 1.73
Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol (2008) 1.72
Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther (2009) 1.34
Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res (2009) 1.30
Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. Mol Pharm (2009) 1.12
NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Control Release (2007) 1.09
Interactions between SIRT1 and AP-1 reveal a mechanistic insight into the growth promoting properties of alumina (Al2O3) nanoparticles in mouse skin epithelial cells. Carcinogenesis (2008) 1.08
Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. Antimicrob Agents Chemother (2012) 1.05
Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res (2008) 1.04
Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. PLoS One (2013) 0.98
Stability of proteins encapsulated in injectable and biodegradable poly(lactide-co-glycolide)-glucose millicylinders. Int J Pharm (2008) 0.97
Rosette nanotubes show low acute pulmonary toxicity in vivo. Int J Nanomedicine (2008) 0.95
Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung (2012) 0.92
Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine (2011) 0.91
PEGylated polyplex with optimized PEG shielding enhances gene introduction in lungs by minimizing inflammatory responses. Mol Ther (2012) 0.84
Particulate matter in cigarette smoke increases ciliary axoneme beating through mechanical stimulation. J Aerosol Med Pulm Drug Deliv (2012) 0.83
Safety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles. AAPS J (2014) 0.80
In vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug delivery. J Control Release (2015) 0.79
Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins. Langmuir (2008) 0.78
Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases. Inflamm Res (2011) 0.78
Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.78
Preparation and characterization of antioxidant nanoparticles composed of chitosan and fucoidan for antibiotics delivery. Mar Drugs (2014) 0.78
Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin. AAPS PharmSciTech (2012) 0.77
Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases. Sci Rep (2014) 0.75
Nanomaterials, inflammation, and tissue engineering. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.75
Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy. Sci Rep (2017) 0.75
Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry (1994) 9.16
Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med (1998) 7.34
A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res (1999) 3.19
Sildenafil treatment for portopulmonary hypertension. Eur Respir J (2006) 2.58
Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med (2000) 2.55
Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J (2010) 2.51
Neoalveolarisation contributes to compensatory lung growth following pneumonectomy in mice. Eur Respir J (2007) 2.11
Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med (2000) 1.95
Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am J Physiol Lung Cell Mol Physiol (2001) 1.85
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 1.80
Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med (1996) 1.79
Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet (1993) 1.74
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol (2000) 1.73
The dorsolateral, suboccipital, transcondylar approach to the lower clivus and anterior portion of the craniocervical junction. Neurosurgery (1991) 1.67
Evaluation of energy metabolism in skeletal muscle of patients with heart failure with gated phosphorus-31 nuclear magnetic resonance. Circulation (1985) 1.63
Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J (2008) 1.62
Bacterial exotoxins and endothelial permeability for water and albumin in vitro. Am J Physiol (1988) 1.61
Characterization of commercially available and synthesized polyethylenimines for gene delivery. J Control Release (2000) 1.59
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J (2008) 1.58
Staphylococcal alpha-toxin-induced PGI2 production in endothelial cells: role of calcium. Am J Physiol (1985) 1.57
Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med (2000) 1.57
Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2000) 1.54
Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm (1998) 1.54
[Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. Pneumologie (2002) 1.48
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J (2010) 1.47
Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol (1985) (1985) 1.44
Staphylococcal alpha-toxin elicits hypertension in isolated rabbit lungs. Evidence for thromboxane formation and the role of extracellular calcium. J Clin Invest (1984) 1.43
Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Crit Care Med (2001) 1.43
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med (1996) 1.42
Characterisation of post-pneumonectomy lung growth in adult mice. Eur Respir J (2004) 1.39
Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release (2005) 1.38
The effect of repeated ozone exposures on inflammatory markers in bronchoalveolar lavage fluid and mucosal biopsies. Am J Respir Crit Care Med (2000) 1.36
Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J (1996) 1.35
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J (2002) 1.35
Psychiatry's new role in corrections. Am J Psychiatry (1969) 1.34
Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost (2000) 1.33
Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm (2000) 1.33
Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines. J Immunol (2000) 1.32
Mechanism of leukotriene generation in polymorphonuclear leukocytes by staphylococcal alpha-toxin. Infect Immun (1987) 1.30
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J (2002) 1.27
Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax (2000) 1.27
Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis (1989) 1.27
In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm (2004) 1.26
The Human Genome Project: view from the National Institutes of Health. J Am Med Womens Assoc (1997) 1.25
Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. Eur Respir J (2008) 1.24
Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res (2001) 1.23
Human endothelial cell activation and mediator release in response to the bacterial exotoxins Escherichia coli hemolysin and staphylococcal alpha-toxin. J Immunol (1997) 1.23
Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)? Am J Physiol Lung Cell Mol Physiol (2000) 1.22
Alveolar JE/MCP-1 and endotoxin synergize to provoke lung cytokine upregulation, sequential neutrophil and monocyte influx, and vascular leakage in mice. Am J Respir Crit Care Med (2001) 1.21
The listerial exotoxins listeriolysin and phosphatidylinositol-specific phospholipase C synergize to elicit endothelial cell phosphoinositide metabolism. J Immunol (1996) 1.17
Human endothelial cell activation and mediator release in response to Listeria monocytogenes virulence factors. Infect Immun (2001) 1.16
Microsurgical unilateral approaches for spinal tumour surgery: eight years' experience in 256 primary operated patients. Acta Neurochir (Wien) (1989) 1.16
Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharm Res (1996) 1.16
Effects of Escherichia coli hemolysin on endothelial cell function. Infect Immun (1990) 1.16
Escherichia coli hemolysin is a potent inductor of phosphoinositide hydrolysis and related metabolic responses in human neutrophils. J Clin Invest (1991) 1.13
Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med (2001) 1.13
Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. J Immunol (1986) 1.13
Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med (1999) 1.13
Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. J Exp Med (1996) 1.12
An introductory orientation to clinical pathology core and on-call responsibilities. Arch Pathol Lab Med (1994) 1.12
Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation (2000) 1.12
Parkinsonism and rest tremor secondary to supratentorial tumours sparing the basal ganglia. Acta Neurochir (Wien) (1995) 1.12
Ex vivo antigen preparation for the serological detection of drug-dependent antibodies in immune haemolytic anaemias. Br J Haematol (1984) 1.11
Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. Br J Haematol (1996) 1.10
SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis. Thorax (2009) 1.10
Listeriolysin is a potent inducer of the phosphatidylinositol response and lipid mediator generation in human endothelial cells. Infect Immun (1996) 1.09
Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene (2012) 1.09
In vivo biocompatibility study of ABA triblock copolymers consisting of poly(L-lactic-co-glycolic acid) A blocks attached to central poly(oxyethylene) B blocks. J Biomed Mater Res (1996) 1.07
The hemolysin of Escherichia coli. Eur J Epidemiol (1988) 1.07
Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells. Pharm Res (2001) 1.07
Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med (2001) 1.06
Pseudomonas aeruginosa cytotoxin stimulates prostacyclin production in cultured pulmonary artery endothelial cells: membrane attack and calcium influx. J Cell Physiol (1985) 1.06
Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J (1997) 1.06
Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clin Microbiol Infect (2011) 1.06
Changes in extracranial arteries in obstructive sleep apnoea. Eur Respir J (2005) 1.05
Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. Am J Respir Cell Mol Biol (1998) 1.04
Tetracycline-HCl-loaded poly(DL-lactide-co-glycolide) microspheres prepared by a spray drying technique: influence of gamma-irradiation on radical formation and polymer degradation. J Control Release (1999) 1.04
Impact of arachidonic versus eicosapentaenoic acid on exotonin-induced lung vascular leakage: relation to 4-series versus 5-series leukotriene generation. Am J Respir Crit Care Med (1997) 1.04
Asymptomatic pulmonary embolism following pacemaker implantation. Pacing Clin Electrophysiol (1986) 1.04
Role of Listeria monocytogenes exotoxins listeriolysin and phosphatidylinositol-specific phospholipase C in activation of human neutrophils. Infect Immun (1999) 1.03
Recombinant human erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteristics. Eur J Pharm Biopharm (1998) 1.01
Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization. Gastroenterology (1991) 1.01
Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. J Control Release (2005) 1.01
Role of Ca2+ and Mg2+ for endothelial permeability of water and albumin in vitro. Lab Invest (1989) 1.00
Freeze-drying and lyopreservation of diblock and triblock poly(lactic acid)-poly(ethylene oxide) (PLA-PEO) copolymer nanoparticles. Pharm Dev Technol (2000) 1.00
Role of endothelial MCP-1 in monocyte adhesion to inflamed human endothelium under physiological flow. Am J Physiol Heart Circ Physiol (2002) 0.99
Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med (1996) 0.99
Ultrasonic atomization for spray drying: a versatile technique for the preparation of protein loaded biodegradable microspheres. J Microencapsul (1999) 0.98
NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. Am J Physiol Lung Cell Mol Physiol (2001) 0.98